Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
MacrogenicsMGNX | Open-market buy | 25/08/19–25/08/20 | 25/08/21 | 100,000 sh2 trades | $1.51avg. | $150,515 | +909.1% | |
Beth Ann SmithVP, Controller & Treasurer | MacrogenicsMGNX | Open-market sale | 25/02/15 | 25/02/19 | 423 sh | $2.56 | $1,082.88 | −4.2% |
MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/04/04 | 24/04/08 | 51,395 sh5 trades | $15.55avg. | $799,148.17 | −100.0% | |
Jeffrey Stuart PetersSenior VP and General Counsel | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/03/06 | 24/03/08 | 19,625 sh | $21.50 | $421,937.5 | −68.8% |
James KarrelsSVP, CFO and Secretary | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/03/04 | 24/03/06 | 30,000 sh | $20.50 | $615,000 | −14.9% |
MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/03/04 | 24/03/06 | 41,159 sh2 trades | $19.76avg. | $813,501.17 | −51.4% | |
Thomas SpitznagelSr VP, Technical Ops | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/03/04 | 24/03/06 | 10,000 sh | $20.00 | $200,000 | −54.6% |
Jeffrey Stuart PetersSenior VP and General Counsel | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/02/26 | 24/02/28 | 16,124 sh | $17.22 | $277,655.28 | −64.4% |
Ezio BonviniSr VP, Research & CSO | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/02/07 | 24/02/07 | 3,334 sh | $18.00 | $60,012 | −4.5% |
MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/02/05 | 24/02/07 | 76,251 sh2 trades | $16.50avg. | $1,258,141.5 | −100.0% | |
Ezio BonviniSr VP, Research & CSO | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/02/01 | 24/02/02 | 13,316 sh | $15.00 | $199,740 | −15.1% |
Ezio BonviniSr VP, Research & CSO | MacrogenicsMGNX | Open-market sale10b5-1 plan | 24/01/19 | 24/01/22 | 13,316 sh | $12.00 | $159,792 | −13.1% |
Ezio BonviniSr VP, Research & CSO | MacrogenicsMGNX | Open-market sale10b5-1 plan | 23/12/20 | 23/12/21 | 18,880 sh | $10.08 | $190,310.4 | −15.7% |
BB Biotech10% Owner | MacrogenicsMGNX | Open-market buy | 23/10/02 | 23/10/04 | 150,000 sh | $4.46 | $669,000 | +1.5% |
Target N. V. Biotech10% Owner | MacrogenicsMGNX | Open-market buy | 23/10/02 | 23/10/04 | 150,000 sh | $4.46 | $669,000 | +1.5% |
BB Biotech10% Owner | MacrogenicsMGNX | Open-market buy | 23/09/07 | 23/09/11 | 200,000 sh | $5.26 | $1,052,000 | +2.1% |
Target N. V. Biotech10% Owner | MacrogenicsMGNX | Open-market buy | 23/09/07 | 23/09/11 | 200,000 sh | $5.26 | $1,052,000 | +2.1% |
Edward HurwitzDirector | MacrogenicsMGNX | Open-market buy | 23/08/30 | 23/09/01 | 15,000 sh | $4.91 | $73,650 | +83.0% |
Jeffrey Stuart PetersSenior VP and General Counsel | MacrogenicsMGNX | Open-market sale | 23/03/10 | 23/03/14 | 5,372 sh | $6.03 | $32,393.16 | −100.0% |
BB Biotech10% Owner | MacrogenicsMGNX | Open-market buy | 23/02/14 | 23/02/16 | 500,000 sh | $5.07 | $2,535,000 | +5.5% |